Belpointe Asset Management LLC purchased a new stake in PAVmed Inc. (NASDAQ:PAVM – Get Rating) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 95,158 shares of the company’s stock, valued at approximately $46,000. Belpointe Asset Management LLC owned 0.10% of PAVmed as of its most recent SEC filing.
A number of other large investors also recently made changes to their positions in PAVM. Private Advisor Group LLC raised its stake in PAVmed by 40.8% during the 1st quarter. Private Advisor Group LLC now owns 31,823 shares of the company’s stock worth $42,000 after buying an additional 9,215 shares during the period. Vanguard Group Inc. raised its stake in PAVmed by 2.9% during the 1st quarter. Vanguard Group Inc. now owns 4,216,982 shares of the company’s stock worth $5,567,000 after buying an additional 116,997 shares during the period. Charles Schwab Investment Management Inc. raised its stake in PAVmed by 5.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 195,167 shares of the company’s stock worth $258,000 after buying an additional 10,458 shares during the period. Verition Fund Management LLC acquired a new stake in PAVmed during the 1st quarter worth $196,000. Finally, State Street Corp raised its stake in PAVmed by 8.8% during the 1st quarter. State Street Corp now owns 1,496,536 shares of the company’s stock worth $1,975,000 after buying an additional 120,691 shares during the period. Institutional investors and hedge funds own 13.98% of the company’s stock.
PAVmed Trading Down 7.5 %
Shares of PAVmed stock opened at $0.38 on Thursday. The company has a market capitalization of $39.33 million, a PE ratio of -0.38 and a beta of 0.84. PAVmed Inc. has a 12 month low of $0.35 and a 12 month high of $2.34. The stock’s fifty day simple moving average is $0.44 and its 200 day simple moving average is $0.53.
PAVmed, Inc is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. Its products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes.
- Get a free copy of the StockNews.com research report on PAVmed (PAVM)
- Toll Brothers Rises On Results, But The Roof Is In Place
- It’s Time To Try On VF Corporation’s 6% Yield
- PetCo Management Getting it Right? Earnings Beat Says Yes
- Axcelis Stock In Buy Range After Chart Breakout, Strong Guidance
- Kohl’s 10% Yield Comes Into High Fashion
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.